Phase I Study of HC-7366 for Acute Myeloid Leukemia

This early-phase study is testing the safety and appropriate dose of a new drug called HC-7366 in patients with acute myeloid leukemia (AML) — a type of blood cancer — whose disease has returned or did not respond to prior treatment. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of AML or a pre-leukemia condition with high blast counts - Your disease has come back or did not respond to prior treatment - There are no remaining standard treatment options available to you - Your liver and kidney function meet minimum health thresholds **You may NOT be eligible if...** - You have a specific subtype of AML called acute promyelocytic leukemia (APL) - You have not received appropriate prior therapies - You have serious organ problems or uncontrolled infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.